Back to search results

Improving Communication and Adherence in Black Breast Cancer Survivors

This study, called "Sisters Informing Sisters" (SIS), is testing a behavioral intervention to help Black women with breast cancer better stick to their treatment plans. The intervention, called SIS TALK Back, involves working with a trained survivor coach and receiving culturally tailored materials. Researchers want to see if this approach improves adherence to treatments like chemotherapy or endocrine therapy (hormone therapy) compared to standard care. You may be able to join if you are a Black woman, 18 or older, recently diagnosed with stage I-III breast cancer, and eligible for chemotherapy or endocrine therapy but haven't started it yet. The study will measure how well participants follow their treatment over 36 months. The current status of this study is unclear.

Study design
This is an interventional study comparing the SIS TALK Back intervention to enhanced usual care. It plans to enroll 250 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 36 months to assess treatment adherence behaviors.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05334732

Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)

Active, Not Recruiting
NAAges 18+InterventionalHealth services
Virginia Commonwealth University
~225 participants
Updated 2026-08-26 on ClinicalTrials.gov
What's tested:SIS TALK Back Intervention

At a glance

Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Assessing Study Adherence Behaviors- Initiation
Measured over 36 Months
+2 more outcomes measured

Conditions

Breast Cancer

Explore related trials

Breast Carcinoma

Where it's being run

3 sites across 2 states
District of Columbia2
Virginia1

Study leadership

  • Vanessa B Sheppard, Ph.D · PRINCIPAL_INVESTIGATOR · Virginia Commonwealth University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Self-identify as Black
Newly diagnosed (\~4 weeks post-definitive surgery and prior to initiation of adjuvant chemotherapy or endocrine therapy) patients (stage I-III)
Eligible for chemotherapy or endocrine therapy according to NCCN guidelines, but have not initiated systemic therapy
Ability to read and speak English
Ability to provide meaningful consent as determined by trained study personnel and/or a member of the patient's care team
No prior cancer treatment (other than skin cancer) in the two years preceding enrollment
Physicians Must be a license doctor of study patient(s)
Ability to speak English

What this trial measures

  • Assessing Study Adherence Behaviors- Initiation36 Months

    Initiation will be measured for all therapies based on the number of participants starting at least one cycle of prescribed therapy

  • Assessing Study Adherence Behaviors- Delay of Adjuvant or Endocrine Therapy.36 Months

    Initiation Delay of therapy will be measured by the number of participant's days from definitive surgery date to the date of her first cycle of adjuvant systemic therapy. Classifications of delay are dichotomized according to published reports (\<60 days primary measure).

  • Assessing Study Adherence Behaviors- Overall Chemotherapy Adherence36 Months

    Overall chemotherapy adherence will be measured by the number of participants that complete chemotherapy. Chemotherapy adherence will be measured as having at least 80% or more of the recommended doses. Adherence will be calculated based on the planned and expected number of cycles divided by the number received (i.e., 6 chemotherapy cycles received/8 expected = 75% adherent).